The Gastrointestinal Cancer Channel is supported with funding from Gilead Sciences (Silver) and Revolution Medicines (Silver).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ASCO 2024 | CheckMate 9DW: the future of checkpoint inhibitors in advanced HCC
Laura Williams Goff, MD, MSCI, MMHC, Vanderbilt-Ingram Cancer Center, Nashville, TN, provides insight on the CheckMate 9DW trial (NCT04039607) of nivolumab plus ipilimumab versus sorafenib or lenvatinib in patients with advanced hepatocellular carcinoma (HCC). The results demonstrated a statistically significant improvement in overall survival (OS) rates for patients receiving nivolumab plus ipilimumab. Additionally, nivolumab plus ipilimumab outperformed both atezolizumab plus bevacizumab, as reported in the IMbrave150 trial (NCT03434379), and durvalumab plus tremelimumab, as seen in the HIMALAYA trial (NCT03298451). This interview took place during the 2024 American Society of Clinical Oncology (ASCO) Meeting in Chicago, IL.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Disclosures
Consulting or Advisory Role – Athenum Consulting; Boehringer Ingelheim; Cardinal Health; Exelixis; QED Therapeutics; Relay Therapeutics
Research Funding – Agios (Inst); ASLAN Pharmaceuticals (Inst); Basilea (Inst); BeiGene (Inst); Bristol-Myers Squibb (Inst); Merck (Inst)
